返回 
加入收藏
孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨孟鲁司特联合布地奈德治疗支气管哮喘（BA）患儿的临床疗效和安全性，以及对BA患儿临床症状、炎症因子和免疫功能的影响。方法：选取2014年1月－2015年12月在我院儿科住院治疗的BA患儿106例，采用随机数字表法分为观察组与对照组，各53例。在对症治疗基础上，对照组患儿给予吸入用布地奈德混悬液400 μg吸入治疗，bid；观察组患儿在对照组治疗基础上给予孟鲁司特钠片口服，5岁以下患儿每次4 mg，qd，5岁及以上患儿每次5 mg，qd。两组患儿疗程均为8周。比较两组患儿的临床疗效，治疗前后的临床症状积分、炎症因子和免疫因子水平，以及不良反应发生情况等。结果：观察组患儿的总有效率（94.34％）明显高于对照组（77.36％），症状缓解时间和肺部体征消失时间明显短于对照组，差异均有统计学意义（P＜0.05）。治疗前，两组患儿的临床症状积分、炎症因子和免疫因子水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患儿日间和夜间症状积分、白细胞介素（IL）-6、IL-8、肿瘤坏死因子α和免疫球蛋白（Ig）E水平均较治疗前明显降低，IgA、IgG水平均较治疗前明显升高，且观察组均明显优于对照组，差异均有统计学意义（P＜0.05）。两组患儿不良反应发生率（5.66％ vs. 7.55％）比较，差异无统计学意义（P＞0.05）。结论：孟鲁司特联合布地奈德有助于下调BA患儿血清炎症因子水平，提高其免疫功能，改善其临床症状，且安全性好。 |
| ABSTRACT： | OBJECTIVE： To investigate clinical efficacy and safety of montelukast combined with budesonide in the treatment of bronchial asthma （BA）， and it effects on clinical symptom， inflammatory factor and immune function of BA children. METHODS： Totally 106 BA children selected from pediatrics department of our hospital during Jan. 2014-Dec. 2015 were divided into observation group and control group according to random number table， with 53 cases in each group. Based on routine treatment， control group was given Budesonide suspension for inhalation 400 μg， bid. Observation group was additionally given Montelukast sodium tablets orally， 4 mg for under 5 years old， qd， 5 mg for 5 years old or older， qd， on the basis of control group. Treatment courses of 2 groups lasted for 8 weeks. Clinical efficacies of 2 groups were compared as well as clinical symptom scores， inflammatory factor and immune factor levels before and after treatment. The occurrence of ADR was also compared between 2 groups. RESULTS： The total response rate of observation group （94.34％） was significantly higher than that of control group （77.36％）； the symptom relief time and lung signs disappearance time were significantly shorter than control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in clinical symptom scores， inflammatory factor and immune factor levels between 2 groups （P＞0.05）. After treatment， daytime and nighttime symptom scores， the levels of IL-6， IL-8， TNF-α and IgE in 2 groups were significantly decreased， while the levels of IgA and IgG were increased significantly； the observation group was significantly better than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （5.66％ vs. 7.55％） （P＜0.05）. CONCLUSIONS： Montelukast combined with budesonide help to reduce the level of serum inflammatory cytokines in BA children， improve immune function and clinical symptoms with good safety. |
| 期刊： | 2017年第28卷第14期 |
| 作者： | 莫丽慧，钟丽花 |
| AUTHORS： | MO Lihui，ZHONG Lihua |
| 关键字： | 孟鲁司特；布地奈德；支气管哮喘；患儿；炎症因子；免疫功能 |
| KEYWORDS： | Montelukast； Budesonide； Bronchial asthma； Pediatric patient； Inflammatory factor； Immune function |
| 阅读数： | 295 次 |
| 本月下载数： | 5 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
